Caisse de depot et placement du Quebec bought a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,023,372 shares of the medical equipment provider's stock, valued at approximately $64,186,000. Caisse de depot et placement du Quebec owned approximately 0.24% of Smith & Nephew SNATS at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Clearstead Trust LLC bought a new position in shares of Smith & Nephew SNATS during the 2nd quarter valued at approximately $25,000. Garner Asset Management Corp bought a new stake in Smith & Nephew SNATS in the fourth quarter worth $27,000. Arax Advisory Partners increased its position in Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider's stock worth $32,000 after purchasing an additional 569 shares during the last quarter. Advisors Asset Management Inc. purchased a new stake in Smith & Nephew SNATS during the fourth quarter valued at $36,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Smith & Nephew SNATS during the third quarter valued at $41,000. 25.64% of the stock is owned by institutional investors.
Smith & Nephew SNATS Price Performance
NYSE SNN opened at $29.14 on Friday. The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS, Inc. has a 52 week low of $28.56 and a 52 week high of $38.79. The company has a fifty day moving average of $30.24 and a two-hundred day moving average of $31.70.
Smith & Nephew SNATS Announces Dividend
The company also recently declared a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be paid a dividend of $0.312 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a dividend yield of 205.0%.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the stock. Weiss Ratings lowered shares of Smith & Nephew SNATS from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, June 11th. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a "hold" rating to a "buy" rating in a research report on Monday. Kepler Capital Markets downgraded shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a report on Thursday, June 4th. Sanford C. Bernstein set a $31.85 price target on shares of Smith & Nephew SNATS in a report on Monday, May 11th. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Smith & Nephew SNATS in a research report on Thursday, August 6th. Two equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $30.93.
Get Our Latest Report on Smith & Nephew SNATS
Smith & Nephew SNATS Company Profile
(
Free Report)
Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.
In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Smith & Nephew SNATS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.
While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
